- Home
- LPCN vs RVPH Comparison
LPCN vs RVPH Comparison
Compare LPCN & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- RVPH
- Stock Information
- Founded
- LPCN 1997
- RVPH 2006
- Country
- LPCN United States
- RVPH United States
- Employees
- LPCN N/A
- RVPH N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- RVPH Health Care
- Exchange
- LPCN Nasdaq
- RVPH Nasdaq
- Market Cap
- LPCN 18.2M
- RVPH 18.1M
- IPO Year
- LPCN N/A
- RVPH N/A
- Fundamental
- Price
- LPCN $2.75
- RVPH $0.58
- Analyst Decision
- LPCN Strong Buy
- RVPH Strong Buy
- Analyst Count
- LPCN 1
- RVPH 6
- Target Price
- LPCN $8.00
- RVPH $3.33
- AVG Volume (30 Days)
- LPCN 59.3K
- RVPH 19.9M
- Earning Date
- LPCN 11-07-2025
- RVPH 11-13-2025
- Dividend Yield
- LPCN N/A
- RVPH N/A
- EPS Growth
- LPCN N/A
- RVPH N/A
- EPS
- LPCN N/A
- RVPH N/A
- Revenue
- LPCN $4,208,119.00
- RVPH N/A
- Revenue This Year
- LPCN N/A
- RVPH N/A
- Revenue Next Year
- LPCN N/A
- RVPH N/A
- P/E Ratio
- LPCN N/A
- RVPH N/A
- Revenue Growth
- LPCN N/A
- RVPH N/A
- 52 Week Low
- LPCN $2.65
- RVPH $0.25
- 52 Week High
- LPCN $6.17
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- LPCN 38.39
- RVPH 52.07
- Support Level
- LPCN $2.75
- RVPH $0.42
- Resistance Level
- LPCN $2.92
- RVPH $0.70
- Average True Range (ATR)
- LPCN 0.14
- RVPH 0.09
- MACD
- LPCN -0.04
- RVPH -0.01
- Stochastic Oscillator
- LPCN 6.12
- RVPH 41.65
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.